Prospects for develo** an hepatitis C virus E1E2‐based nanoparticle vaccine
EA Toth, AK Andrianov… - Reviews in Medical …, 2023 - Wiley Online Library
Globally, more than 58 million people are chronically infected with Hepatitis C virus (HCV)
with 1.5 million new infections occurring each year. An effective vaccine for HCV is therefore …
with 1.5 million new infections occurring each year. An effective vaccine for HCV is therefore …
[HTML][HTML] How different viruses perturb host cellular machinery via short linear motifs
The virus interacts with its hosts by develo** protein-protein interactions. Most viruses
employ protein interactions to imitate the host protein: A viral protein with the same amino …
employ protein interactions to imitate the host protein: A viral protein with the same amino …
Induction of cross-neutralizing antibodies by a permuted hepatitis C virus glycoprotein nanoparticle vaccine candidate
Hepatitis C virus (HCV) infection affects approximately 58 million people and causes~
300,000 deaths yearly. The only target for HCV neutralizing antibodies is the highly …
300,000 deaths yearly. The only target for HCV neutralizing antibodies is the highly …
Structure of the hepatitis C virus E1E2 glycoprotein complex
Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease, cirrhosis, and
hepatocellular carcinoma in humans and afflicts more than 58 million people worldwide. The …
hepatocellular carcinoma in humans and afflicts more than 58 million people worldwide. The …
Structure of engineered hepatitis C virus E1E2 ectodomain in complex with neutralizing antibodies
MC Metcalf, BM Janus, R Yin, R Wang… - Nature …, 2023 - nature.com
Hepatitis C virus (HCV) is a major global health burden as the leading causative agent of
chronic liver disease and hepatocellular carcinoma. While the main antigenic target for HCV …
chronic liver disease and hepatocellular carcinoma. While the main antigenic target for HCV …
The hepatitis C virus envelope protein complex is a dimer of heterodimers
EH Augestad, C Holmboe Olesen, C Grønberg… - Nature, 2024 - nature.com
Fifty-eight million individuals worldwide are affected by chronic hepatitis C virus (HCV)
infection, a primary driver of liver cancer for which no vaccine is available. The HCV …
infection, a primary driver of liver cancer for which no vaccine is available. The HCV …
A nanoparticle-based hepatitis C virus vaccine with enhanced potency
Despite the emergence of new direct-acting antivirals, hepatitis C virus (HCV) chronic
infection and its consequent fibrosis and hepatocarcinoma remain a significant burden for …
infection and its consequent fibrosis and hepatocarcinoma remain a significant burden for …
Chemical and biological conjugation strategies for the development of multivalent protein vaccine nanoparticles
The development of subunit vaccine platforms has been of considerable interest due to their
good safety profile and ability to be adapted to new antigens, compared to other vaccine …
good safety profile and ability to be adapted to new antigens, compared to other vaccine …
Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening
JM Pfaff-Kilgore, E Davidson, K Kadash-Edmondson… - Cell reports, 2022 - cell.com
The E1 and E2 envelope proteins of hepatitis C virus (HCV) form a heterodimer that drives
virus-host membrane fusion. Here, we analyze the role of each amino acid in E1E2 function …
virus-host membrane fusion. Here, we analyze the role of each amino acid in E1E2 function …
[HTML][HTML] Surfactant proteins A and D: trimerized innate immunity proteins with an affinity for viral fusion proteins
Innate recognition of viruses is an essential part of the immune response to viral pathogens.
This is integral to the maintenance of healthy lungs, which are free from infection and …
This is integral to the maintenance of healthy lungs, which are free from infection and …